Summary

Global Diabetic Neuropathy Treatment Market is valued approximately USD 4.03 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 7.72% over the forecast period 2023-2030. Diabetic neuropathy treatment encompasses a range of strategies aimed at managing the symptoms and complications associated with nerve damage caused by diabetes. These treatments focus on alleviating pain, improving nerve function, and preventing further damage. Common approaches to diabetic neuropathy treatment include medication therapy, lifestyle modifications, and alternative therapies. The Diabetic Neuropathy Treatment market is expanding because of factors such as rising prevalence of diabetes, rising geriatric population and increasing healthcare expenditure across worldwide.

The rising prevalence of diabetes worldwide is a significant driver of the diabetic neuropathy treatment market. As the number of individuals with diabetes continues to grow, so does the incidence of diabetic neuropathy, creating a larger patient pool in need of treatment. As per data from the International Diabetes Federation, the year 2022 witnessed approximately 537 million adults aged 20 to 79 affected by diabetes, translating to 1 in 10 individuals globally. Projections indicate a steady increase, with an estimated rise to 643 million by 2030 and further escalation to 783 million by 2045. In addition, rising research and development activities to discover new drugs and therapies and growing focus on patient-centric care are creating new opportunities to the market growth. However, lack of awareness and education and side effects of medications stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Diabetic Neuropathy Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the the region's sophisticated healthcare infrastructure and substantial healthcare expenditure, fostering an environment conducive to the uptake of advanced treatments for diabetic neuropathy. Leading industry players such as Abbott, Pfizer Inc., Eli Lilly, and Johnson & Johnson have established operational footholds in this region, further fueling market expansion. Additionally, the imminent completion of Neuralace Medical's Painful Diabetic Neuropathy (PDN) label expansion study, coupled with the potential FDA clearance for its non-invasive treatment, stands poised to revolutionize the diabetic neuropathy market landscape in North America. Europe is expected to grow at a fastest rate during the forecast period, owing to factors such as positive reinforcement due to escalating government funding directed towards enhancing healthcare infrastructure and supporting research initiatives. Notably, nonprofit organizations like the Central European Diabetes Association (CEDA) engage in collaborative efforts with pharmaceutical companies to drive the development of innovative products, further contributing to market growth.

Major market player included in this report are:
Pfizer Inc.
Eli Lilly and Company
Johnson & Johnson
Abbott Laboratories
Novo Nordisk A/S
Astellas Pharma Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Boehringer Ingelheim International GmbH

Recent Developments in the Market:
 In December 2023, Vertex Pharmaceuticals achieved FDA approval for its CRISPR-based gene editing therapy, marking a strategic milestone in its focus on advancing non-opioid pain management drugs. Leveraging the promising results from Vertex's phase 2 clinical trial of VX-548, this emphasis on alternative pain relief methods reflects the growing demand for safer and more efficient treatments for diabetic peripheral neuropathy. By addressing this critical need for innovative solutions, Vertex Pharmaceuticals secures a competitive advantage in the market.
 In July 2023, Asprius Lifesciences, an Indian pharmaceutical company, unveiled a new treatment for Diabetic Neuropathy, a condition characterized by nerve damage in peripheral body areas. Notably, the company has filed a patent for a Fixed-Dose Combination (FDC), showcasing potential in tackling peripheral neuropathy. This significant development positions Asprius as a formidable contender in the global market, meeting the widespread demand for effective solutions.

Global Diabetic Neuropathy Treatment Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Disorder Type, Drug Class, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
 Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Disorder Type:
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Drug Class:
Capsaicin
Opioid
Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Other

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Diabetic Neuropathy Treatment Market, by Region, 2020-2030 (USD Billion)
1.2.2. Diabetic Neuropathy Treatment Market, by Disorder Type, 2020-2030 (USD Billion)
1.2.3. Diabetic Neuropathy Treatment Market, by Drug Class, 2020-2030 (USD Billion)
1.2.4. Diabetic Neuropathy Treatment Market, by Distribution Channel, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Diabetic Neuropathy Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Diabetic Neuropathy Treatment Market Dynamics
3.1. Diabetic Neuropathy Treatment Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Rising prevalence of diabetes
3.1.1.2. Rising geriatric population
3.1.1.3. Increasing healthcare expenditure across worldwide
3.1.2. Market Challenges
3.1.2.1. Lack of awareness and education
3.1.2.2. Side effects of medications
3.1.3. Market Opportunities
3.1.3.1. Rising research and development activities to discover new drugs and therapies
3.1.3.2. Growing focus on patient-centric care
Chapter 4. Global Diabetic Neuropathy Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Diabetic Neuropathy Treatment Market, by Disorder Type
5.1. Market Snapshot
5.2. Global Diabetic Neuropathy Treatment Market by Disorder Type, Performance - Potential Analysis
5.3. Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Disorder Type 2020-2030 (USD Billion)
5.4. Diabetic Neuropathy Treatment Market, Sub Segment Analysis
5.4.1. Peripheral Neuropathy
5.4.2. Autonomic Neuropathy
5.4.3. Proximal Neuropathy
5.4.4. Focal Neuropathy
Chapter 6. Global Diabetic Neuropathy Treatment Market, by Drug Class
6.1. Market Snapshot
6.2. Global Diabetic Neuropathy Treatment Market by Drug Class, Performance - Potential Analysis
6.3. Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
6.4. Diabetic Neuropathy Treatment Market, Sub Segment Analysis
6.4.1. Capsaicin
6.4.2. Opioid
6.4.3. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
6.4.4. Antidepressants
6.4.5. Others
Chapter 7. Global Diabetic Neuropathy Treatment Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Diabetic Neuropathy Treatment Market by Distribution Channel, Performance - Potential Analysis
7.3. Global Diabetic Neuropathy Treatment Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
7.4. Diabetic Neuropathy Treatment Market, Sub Segment Analysis
7.4.1. Hospitals Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Other
Chapter 8. Global Diabetic Neuropathy Treatment Market, Regional Analysis
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Diabetic Neuropathy Treatment Market, Regional Market Snapshot
8.4. North America Diabetic Neuropathy Treatment Market
8.4.1. U.S. Diabetic Neuropathy Treatment Market
8.4.1.1. Disorder Type breakdown estimates & forecasts, 2020-2030
8.4.1.2. Drug Class breakdown estimates & forecasts, 2020-2030
8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Diabetic Neuropathy Treatment Market
8.5. Europe Diabetic Neuropathy Treatment Market Snapshot
8.5.1. U.K. Diabetic Neuropathy Treatment Market
8.5.2. Germany Diabetic Neuropathy Treatment Market
8.5.3. France Diabetic Neuropathy Treatment Market
8.5.4. Spain Diabetic Neuropathy Treatment Market
8.5.5. Italy Diabetic Neuropathy Treatment Market
8.5.6. Rest of Europe Diabetic Neuropathy Treatment Market
8.6. Asia-Pacific Diabetic Neuropathy Treatment Market Snapshot
8.6.1. China Diabetic Neuropathy Treatment Market
8.6.2. India Diabetic Neuropathy Treatment Market
8.6.3. Japan Diabetic Neuropathy Treatment Market
8.6.4. Australia Diabetic Neuropathy Treatment Market
8.6.5. South Korea Diabetic Neuropathy Treatment Market
8.6.6. Rest of Asia Pacific Diabetic Neuropathy Treatment Market
8.7. Latin America Diabetic Neuropathy Treatment Market Snapshot
8.7.1. Brazil Diabetic Neuropathy Treatment Market
8.7.2. Mexico Diabetic Neuropathy Treatment Market
8.8. Middle East & Africa Diabetic Neuropathy Treatment Market
8.8.1. Saudi Arabia Diabetic Neuropathy Treatment Market
8.8.2. South Africa Diabetic Neuropathy Treatment Market
8.8.3. Rest of Middle East & Africa Diabetic Neuropathy Treatment Market

Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Pfizer Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Eli Lilly and Company
9.3.3. Johnson & Johnson
9.3.4. Abbott Laboratories
9.3.5. Novo Nordisk A/S
9.3.6. Astellas Pharma Inc.
9.3.7. GlaxoSmithKline plc
9.3.8. Merck & Co., Inc.
9.3.9. Teva Pharmaceutical Industries Ltd.
9.3.10. Boehringer Ingelheim International GmbH
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption